Literature DB >> 24478770

Role of poly-proline motif in HIV-2 Vpx expression.

Ariko Miyake1, Yasuyuki Miyazaki1, Mikako Fujita2, Masako Nomaguchi1, Akio Adachi1.   

Abstract

Entities:  

Keywords:  HIV-2; PPM; SIV; Vpr; Vpx

Year:  2014        PMID: 24478770      PMCID: PMC3904113          DOI: 10.3389/fmicb.2014.00024

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


× No keyword cloud information.
Human and simian immunodeficiency viruses (HIV and SIVs) contain several auxiliary genes not found in other retroviruses. These genes are thought to be functionally important for optimal viral replication and persistence in infected individuals. Primate lentiviruses can be classified by the composition of these accessory genes. While viruses of the HIV type1 (HIV-1) group have vif, vpr, vpu, and nef genes, those of the HIV-2 group carry vif, vpx, vpr, and nef genes (Fujita et al., 2010). Vpx protein encoded by the vpx gene is unique to non-HIV-1 viruses, and is essential for viral replication in macrophages in contrast to its structural paralog Vpr (Fujita et al., 2010). The most outstanding sequence feature to distinguish Vpx from Vpr is the presence of poly-proline motif (PPM) at its C-terminal region. We have recently shown, by in vitro and in vivo assay systems, that the PPM in HIV-2 Vpx is critical for its efficient translation (Miyake et al., 2014). Although PPM consisting of seven consecutive prolines has been demonstrated to be required for efficient HIV-2 Vpx translation, thereby acquiring viral infectivity in macrophages, the effects of PPM mutations on the degradation of Vpx in cells was not formally analyzed as yet (Fujita et al., 2008; Miyake et al., 2014). Therefore, in this study, we asked whether the PPM plays a role in keeping away from proteasomal and/or lysosomal degradation (Figure 1). In order to assess this, we used various expression plasmids for HIV-2 Vpx (pEF-Fvpx series) described in a previous study (Miyake et al., 2014): wild-type (WT) plasmid has the vpx gene derived from HIV-2 GL-AN clone (Kawamura et al., 1994); mutants 103/4A and 106/4A have four consecutive alanine-substitutions at the site of P103-P106 and P106-P109, respectively, and have been shown to express a low/minimum level of mutant Vpx proteins in cells (Figure 1A); a negative control is a frame-shift mutant pEF-FxSt that lacks Vpx expression (ΔVpx).
Figure 1

Steady-state levels of various Vpx-PPM mutants in cells as monitored by Western blotting. (A) Structure of the FLAG-tagged HIV-2 GL-AN Vpx construct. Numerals above the schema represent amino acid numbers of the Vpx protein. Positions of lysine and glutamine residues mutated are indicated. (B) Expression of Vpx-PPM mutants in the presence of a proteasome inhibitor MG-132 or a lysosome inhibitor Bafilomycin A1. (C) Expression of lysine-mutants with or without 106/4A mutation. (D) Expression of Q76A mutants with or without 106/4A mutation. For (B) to (D) experiments, 293T cells were transfected with the plasmids indicated, and harvested for Western blotting 24 h later. To examine lysosomal and proteasomal degradation processes (B), 100 nM of BafilomycinA1 (Yoshimori et al., 1991) and 7.5 μM of MG-132 (McCulley and Ratner, 2012) were added at 5 and 16 h post-transfection, respectively. WT, pEF-Fvpx; ΔVpx, pEF-FxSt.

Steady-state levels of various Vpx-PPM mutants in cells as monitored by Western blotting. (A) Structure of the FLAG-tagged HIV-2 GL-AN Vpx construct. Numerals above the schema represent amino acid numbers of the Vpx protein. Positions of lysine and glutamine residues mutated are indicated. (B) Expression of Vpx-PPM mutants in the presence of a proteasome inhibitor MG-132 or a lysosome inhibitor Bafilomycin A1. (C) Expression of lysine-mutants with or without 106/4A mutation. (D) Expression of Q76A mutants with or without 106/4A mutation. For (B) to (D) experiments, 293T cells were transfected with the plasmids indicated, and harvested for Western blotting 24 h later. To examine lysosomal and proteasomal degradation processes (B), 100 nM of BafilomycinA1 (Yoshimori et al., 1991) and 7.5 μM of MG-132 (McCulley and Ratner, 2012) were added at 5 and 16 h post-transfection, respectively. WT, pEF-Fvpx; ΔVpx, pEF-FxSt. Various expression plasmids were transfected into human 293T cells (Lebkowski et al., 1985) as described before (Adachi et al., 1986), and the amounts of WT and mutant Vpx proteins produced in cells in the absence or presence of a proteasome inhibitor MG-132 (Fujita et al., 2004; McCulley and Ratner, 2012) were comparatively examined by Western blotting (Miyake et al., 2014). A drastic reduction in Vpx expression was observed for mutants 103/4A and 106/4A, 106/4A in particular, both in the absence and presence of MG-132 (Figure 1B). These results showed that neither of these mutants could be rescued with MG-132, suggesting no involvement of the PPM in the proteasome-mediated degradation. Similarly, a lysosome inhibitor Bafilomycin A1 (Yoshimori et al., 1991) did not affect much the level of 103/4A and 106/4A in transfected 293T cells, although a small increase was observed for both mutants (Figure 1B). These results suggested that the low expression level of these PPM mutants may not be attributable to the lysosomal degradation. Proteasomal degradation is generally triggered by the polyubiquitin modification of lysine residues in a protein. There are three lysines in the Vpx of HIV-2 GL-AN clone (Khamsri et al., 2006) (Figure 1A). We generated several clones carrying mutations in these residues. Furthermore, we focused on the 76th glutamine residue (Figure 1A). This amino acid has been reported to interact with DCAF1 for formation of Cullin4-based E3 ubiquitin ligase complex to degrade an anti-HIV restriction factor SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011) by proteasome (Le Rouzic et al., 2007; Srivastava et al., 2008). Mutants K68R, K77R, K84R, and Q76A with or without the 106/4A mutation were constructed as described previously (Miyake et al., 2014) (Figure 1A), and examined for their expression in transfected cells (Figures 1C,D). As shown in Figure 1C, only one clone with K84R and 106/4A mutations showed a slight enhancement in agreement with a previous report (Srivastava et al., 2008). Moreover, no significant effect was observed for a mutant carrying Q76A and 106/4A mutations (Figure 1D). These results also suggested that PPM may not be associated with the proteasome-mediated degradation. In total, proteasomal or lysosomal degradation does not account for the extremely low expression level of Vpx exhibited by the PPM mutants. This is consistent with our previous conclusion that PPM is critical for efficient translation of Vpx (Miyake et al., 2014). Molecular mechanism by which PPM enhances Vpx translation to a remarkable extent needs to be determined.
  14 in total

1.  Functional region mapping of HIV-2 Vpx protein.

Authors:  Mikako Fujita; Masami Otsuka; Masako Nomaguchi; Akio Adachi
Journal:  Microbes Infect       Date:  2008-08-14       Impact factor: 2.700

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection.

Authors:  Anna McCulley; Lee Ratner
Journal:  Virology       Date:  2012-03-03       Impact factor: 3.616

4.  Poly-proline motif in HIV-2 Vpx is critical for its efficient translation.

Authors:  Ariko Miyake; Mikako Fujita; Haruna Fujino; Ryoko Koga; Sogo Kawamura; Masami Otsuka; Hirotaka Ode; Yasumasa Iwatani; Yosuke Sakai; Naoya Doi; Masako Nomaguchi; Akio Adachi; Yasuyuki Miyazaki
Journal:  J Gen Virol       Date:  2013-10-10       Impact factor: 3.891

5.  HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase.

Authors:  Erwann Le Rouzic; Nadia Belaïdouni; Emilie Estrabaud; Marina Morel; Jean-Christophe Rain; Catherine Transy; Florence Margottin-Goguet
Journal:  Cell Cycle       Date:  2007-01-17       Impact factor: 4.534

6.  Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation.

Authors:  Mikako Fujita; Hirofumi Akari; Akiko Sakurai; Akiko Yoshida; Tomoki Chiba; Keiji Tanaka; Klaus Strebel; Akio Adachi
Journal:  Microbes Infect       Date:  2004-07       Impact factor: 2.700

7.  Simian virus 40 replication in adenovirus-transformed human cells antagonizes gene expression.

Authors:  J S Lebkowski; S Clancy; M P Calos
Journal:  Nature       Date:  1985 Sep 12-18       Impact factor: 49.962

8.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.

Authors:  T Yoshimori; A Yamamoto; Y Moriyama; M Futai; Y Tashiro
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

9.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.

Authors:  Kasia Hrecka; Caili Hao; Magda Gierszewska; Selene K Swanson; Malgorzata Kesik-Brodacka; Smita Srivastava; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection.

Authors:  Smita Srivastava; Selene K Swanson; Nicolas Manel; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  PLoS Pathog       Date:  2008-05-09       Impact factor: 6.823

View more
  1 in total

1.  Expression Profiles of Vpx/Vpr Proteins Are Co-related with the Primate Lentiviral Lineage.

Authors:  Yosuke Sakai; Ariko Miyake; Naoya Doi; Hikari Sasada; Yasuyuki Miyazaki; Akio Adachi; Masako Nomaguchi
Journal:  Front Microbiol       Date:  2016-08-03       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.